The OUTBACK trial - the role of adjuvant chemotherapy in locally advanced cervical cancer

这项国际随机第三阶段试验将测试在接受标准化疗放射治疗后，对局部晚期宫颈癌妇女进行额外化疗的价值。这样做的目的是提高这些妇女的存活率，她们中的许多人在治疗后疾病复发的可能性为40%或更高。这项试验是在澳大利亚设计的，并在多个国家开放，澳大利亚新西兰妇科肿瘤学小组(ANZGOG)是牵头小组。

This international randomized phase III trial will test the value of giving additional chemotherapy treatment to women with locally advanced cervix cancer following standard chemo-radiation treatment. The aim is to improve survival rates for these women, many of whom have a 40% or greater chance of their disease relapsing after treatment. The trial has been designed in Australia, and is open in multiple countries with Australia New Zealand Gynaecological Oncology Group (ANZGOG) as the lead group.